Clear All
11888 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
59651-0465-29 59651-0465 SUNITINIB MALATE SUNITINIB MALATE 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Mar 14, 2024 In Use
60505-3802-02 60505-3802 Nilotinib Nilotinib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral May 23, 2025 In Use
31722-0297-30 31722-0297 IMATINIB MESYLATE IMATINIB MESYLATE 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Apr 14, 2025 In Use
83076-1100-06 83076-1100 Ensartinib ENSACOVE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK, ROS1, MET Oral Apr 30, 2025 In Use
59651-0545-15 59651-0545 DASATINIB DASATINIB 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Apr 22, 2025 In Use
50419-0171-06 50419-0171 Regorafenib Stivarga 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl Oral May 1, 2021 In Use
82293-0016-10 82293-0016 Sunitinib Malate Sunitinib Malate 37.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral May 1, 2024 In Use
63304-0096-30 63304-0096 Erlotinib Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov 5, 2019 In Use
69097-0577-74 69097-0577 nilotinib NILCEYA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral May 30, 2025 In Use
00480-4184-89 00480-4184 Pazopanib Pazopanib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, PDGFR, FGFR, Kit, Itk, Lck, c-Fms Oral Oct 20, 2023 In Use
63304-0094-27 63304-0094 Sunitinib malate Sunitinib malate 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Dec 25, 2019 In Use
70771-1394-05 70771-1394 Imatinib mesylate Imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan 21, 2021 In Use
83858-0101-60 83858-0101 Dasatinib PHYRAGO 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 1, 2024 In Use
57962-0070-28 57962-0070 Ibrutinib IMBRUVICA 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Dec 20, 2017 In Use
42388-0024-37 42388-0024 Cabozantinib CABOMETYX 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Feb 27, 2019 In Use
82293-0022-10 82293-0022 Pazopanib hydrochloride Pazopanib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, PDGFR, FGFR, Kit, Itk, Lck, c-Fms Oral Apr 24, 2024 In Use
50419-0488-58 50419-0488 Sorafenib Nexavar 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, RET, CRAF, BRAF Oral Dec 20, 2005 In Use
63020-0040-12 63020-0040 Mobocertinib EXKIVITY 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Sep 15, 2021 Mar 31, 2025 No Longer Used
43598-0045-63 43598-0045 SUNITINIB MALATE SUNITINIB MALATE 12.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Nov 30, 2022 In Use
00597-0138-30 00597-0138 Afatinib Gilotrif 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Aug 8, 2013 In Use
43598-0602-30 43598-0602 Dasatinib Dasatinib 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
00078-0649-13 00078-0649 Imatinib Mesylate Gleevec 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 1, 2024 In Use
65162-0795-09 65162-0795 Imatinib Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb 8, 2019 In Use
57894-0080-60 57894-0080 Lazertinib LAZCLUZE 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Aug 20, 2024 In Use
50419-0390-01 50419-0390 LAROTRECTINIB VITRAKVI 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor TRK Oral Jul 26, 2019 In Use

Found 11888 results — Export these results